An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)
Clinical trial NCT01595009 · COMPLETED
Trial details
- NCT number
- NCT01595009
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2011-04-27
- Primary completion
- 2016-08-09
- Enrollment
- 246
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.